

Stephen A Graves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8489219/publications.pdf>

Version: 2024-02-01

67
papers

2,232
citations

186265

28
h-index

233421

45
g-index

68
all docs

68
docs citations

68
times ranked

3489
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Quantification of uptake in pelvis ^{18}F FLT PET-CT images using a 3D localization and segmentation CNN. Medical Physics, 2022, 49, 1585-1598. | 3.0 | 6 |
| 2 | SIR-Spheres activity measurements reveal systematic miscalibration. Journal of Nuclear Medicine, 2022, jnumed.121.262650. | 5.0 | 5 |
| 3 | Monte Carlo evaluation of hypothetical long axial field-of-view PET scanner using GE Discovery MI PET front-end architecture. Medical Physics, 2022, 49, 1139-1152. | 3.0 | 7 |
| 4 | The Impact of Radiopharmaceutical Therapy on Renal Function. Seminars in Nuclear Medicine, 2022, 52, 467-474. | 4.6 | 9 |
| 5 | Practical Considerations for Implementation of ^{177}Lu -DOTATATE Neuroendocrine Tumor Treatment Programs. Journal of Nuclear Medicine Technology, 2022, 50, 195-202. | 0.8 | 0 |
| 6 | Radiopharmaceutical Chemistry and Drug Development—What's Changed?. Seminars in Radiation Oncology, 2021, 31, 3-11. | 2.2 | 11 |
| 7 | Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Seminars in Radiation Oncology, 2021, 31, 37-44. | 2.2 | 17 |
| 8 | Addition of ^{131}I -MIBG to PRRT (^{90}Y -DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2021, 62, 1274-1277. | 5.0 | 11 |
| 9 | Imaging and dosimetric characteristics of ^{67}Cu . Physics in Medicine and Biology, 2021, 66, 035002. | 3.0 | 17 |
| 10 | Proton-induced reactions on Fe, Cu, and Ti from threshold to 55 MeV. European Physical Journal A, 2021, 57, 1. | 2.5 | 5 |
| 11 | Half-life of ^{67}Cu . Journal of Physics Communications, 2021, 5, 085007. | 1.2 | 3 |
| 12 | Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 12095. | 4.1 | 13 |
| 13 | Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 12S-22S. | 5.0 | 14 |
| 14 | Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. Journal of Nuclear Medicine, 2021, 62, 3S-11S. | 5.0 | 19 |
| 15 | Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities. Journal of Nuclear Medicine, 2021, 62, 48S-59S. | 5.0 | 11 |
| 16 | Absorbed dose distributions from beta-decaying radionuclides: Experimental validation of Monte Carlo tools for radiopharmaceutical dosimetry. Medical Physics, 2020, 47, 5779-5790. | 3.0 | 5 |
| 17 | Polyazamacrocyclic Ligands Facilitate ^{89}Zr Radiochemistry and Yield ^{89}Zr Complexes with Remarkable Stability. Inorganic Chemistry, 2020, 59, 17473-17487. | 4.0 | 13 |
| 18 | Commissioning of a 1.5T Elekta Unity MR-Linac: A single institution experience. Journal of Applied Clinical Medical Physics, 2020, 21, 160-172. | 1.9 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | 203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 7003-7031. | 2.4 | 23 |
| 20 | Dose point kernels for 2,174 radionuclides. <i>Medical Physics</i> , 2019, 46, 5284-5293. | 3.0 | 25 |
| 21 | Isotope harvesting at FRIB: additional opportunities for scientific discovery. <i>Journal of Physics G: Nuclear and Particle Physics</i> , 2019, 46, 100501. | 3.6 | 35 |
| 22 | Commissioning and performance evaluation of RadCalc for the Elekta unity MRI linac. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 54-62. | 1.9 | 30 |
| 23 | Evaluation of a chloride-based ⁸⁹ Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction resin. <i>Nuclear Medicine and Biology</i> , 2018, 64-65, 1-7. | 0.6 | 17 |
| 24 | In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica Nanosystem. <i>Nano-Micro Letters</i> , 2018, 10, 65. | 27.0 | 31 |
| 25 | Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for <i>In Vivo</i> Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. <i>Journal of Biomedical Nanotechnology</i> , 2018, 14, 900-909. | 1.1 | 29 |
| 26 | Excitation functions for (p,x) reactions of niobium in the energy range of Ep = 40–90 MeV. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2018, 429, 53-74. | 1.4 | 15 |
| 27 | Radiomanganese PET Detects Changes in Functional β^2 -Cell Mass in Mouse Models of Diabetes. <i>Diabetes</i> , 2017, 66, 2163-2174. | 0.6 | 32 |
| 28 | Preparation and in vivo characterization of ⁵¹ MnCl ₂ as PET tracer of Ca ²⁺ channel-mediated transport. <i>Scientific Reports</i> , 2017, 7, 3033. | 3.3 | 22 |
| 29 | CD38 as a PET Imaging Target in Lung Cancer. <i>Molecular Pharmaceutics</i> , 2017, 14, 2400-2406. | 4.6 | 25 |
| 30 | ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. <i>Molecular Pharmaceutics</i> , 2017, 14, 1646-1655. | 4.6 | 36 |
| 31 | Optimized procedures for manganese-52: Production, separation and radiolabeling. <i>Applied Radiation and Isotopes</i> , 2017, 121, 38-43. | 1.5 | 37 |
| 32 | Radiolabeled, Antibody-Conjugated Manganese Oxide Nanoparticles for Tumor Vasculature Targeted Positron Emission Tomography and Magnetic Resonance Imaging. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 38304-38312. | 8.0 | 47 |
| 33 | Cyclotron production and radiochemical separation of ⁵⁵ Co and ^{58m} Co from ⁵⁴ Fe, ⁵⁸ Ni and ⁵⁷ Fe targets. <i>Applied Radiation and Isotopes</i> , 2017, 130, 90-101. | 1.5 | 30 |
| 34 | Half-life of Mn ⁵¹ . <i>Physical Review C</i> , 2017, 96, . | 2.9 | 4 |
| 35 | Simplified and reproducible radiochemical separations for the production of high specific activity ⁶¹ Cu, ⁶⁴ Cu, ⁸⁶ Y and ⁵⁵ Co. <i>AIP Conference Proceedings</i> , 2017, , . | 0.4 | 3 |
| 36 | Earth, air, fire and water: A targetry quartet. <i>AIP Conference Proceedings</i> , 2017, , . | 0.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 162-168. | 5.0 | 152 |
| 38 | Radiobromine production, isolation and radiosynthesis for the development of a novel prostate cancer radiotherapeutic agent. <i>AIP Conference Proceedings</i> , 2017, , . | 0.4 | 2 |
| 39 | Auger electron-based targeted radioimmunotherapy with ⁵⁸ mCo, a feasibility study. <i>AIP Conference Proceedings</i> , 2016, , . | 0.4 | 6 |
| 40 | Dynamic Positron Emission Tomography Imaging of Renal Clearable Gold Nanoparticles. <i>Small</i> , 2016, 12, 2775-2782. | 10.0 | 66 |
| 41 | Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3821-3830. | 7.0 | 30 |
| 42 | Long circulating reduced graphene oxide-iron oxide nanoparticles for efficient tumor targeting and multimodality imaging. <i>Nanoscale</i> , 2016, 8, 12683-12692. | 5.6 | 58 |
| 43 | Spot-welding solid targets for high current cyclotron irradiation. <i>Applied Radiation and Isotopes</i> , 2016, 118, 350-353. | 1.5 | 13 |
| 44 | Nuclear excitation functions of proton-induced reactions (E _p = 35-90 MeV) from Fe, Cu, and Al. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2016, 386, 44-53. | 1.4 | 19 |
| 45 | Engineering Intrinsically Zirconium- ⁸⁹ Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies. <i>Advanced Science</i> , 2016, 3, 1600122. | 11.2 | 70 |
| 46 | Uptake and retention of manganese contrast agents for PET and MRI in the rodent brain. <i>Contrast Media and Molecular Imaging</i> , 2016, 11, 371-380. | 0.8 | 22 |
| 47 | ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2169-2179. | 6.4 | 23 |
| 48 | Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 17955-17963. | 8.0 | 48 |
| 49 | Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. <i>Biomaterials</i> , 2016, 100, 101-109. | 11.4 | 61 |
| 50 | PET Imaging of VEGFR-2 Expression in Lung Cancer with ⁶⁴ Cu-Labeled Ramucirumab. <i>Journal of Nuclear Medicine</i> , 2016, 57, 285-290. | 5.0 | 30 |
| 51 | A porphyrin-PEG polymer with rapid renal clearance. <i>Biomaterials</i> , 2016, 76, 25-32. | 11.4 | 60 |
| 52 | Development of a novel linearly-filled Derenzo microPET phantom. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 199-204. | 1.0 | 7 |
| 53 | ⁵² Mn Production for PET/MRI Tracking Of Human Stem Cells Expressing Divalent Metal Transporter 1 (DMT1). <i>Theranostics</i> , 2015, 5, 227-239. | 10.0 | 80 |
| 54 | PET of Follicle-Stimulating Hormone Receptor: Broad Applicability to Cancer Imaging. <i>Molecular Pharmaceutics</i> , 2015, 12, 403-410. | 4.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Red Fluorescent Zinc Oxide Nanoparticle: A Novel Platform for Cancer Targeting. ACS Applied Materials & Interfaces, 2015, 7, 3373-3381. | 8.0 | 84 |
| 56 | Hexamodal Imaging with Porphyrin-Phospholipid-Coated Upconversion Nanoparticles. Advanced Materials, 2015, 27, 1785-1790. | 21.0 | 189 |
| 57 | PET Imaging of Abdominal Aortic Aneurysm with ⁶⁴ Cu-Labeled Anti-CD105 Antibody Fab Fragment. Journal of Nuclear Medicine, 2015, 56, 927-932. | 5.0 | 35 |
| 58 | ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1295-1303. | 6.4 | 36 |
| 59 | PET of c-Met in Cancer with ⁶⁴ Cu-Labeled Hepatocyte Growth Factor. Journal of Nuclear Medicine, 2015, 56, 758-763. | 5.0 | 21 |
| 60 | <i>In Vivo</i> Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. ACS Nano, 2015, 9, 3926-3934. | 14.6 | 155 |
| 61 | Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12806-12811. | 7.1 | 54 |
| 62 | Novel Preparation Methods of ⁵² Mn for ImmunoPET Imaging. Bioconjugate Chemistry, 2015, 26, 2118-2124. | 3.6 | 74 |
| 63 | Evaluation of two novel ⁶⁴ Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin $\alpha_v\beta_3$. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1859-1868. | 6.4 | 17 |
| 64 | Development and characterization of a hexamodal imaging nanoparticle. , 2015, , . | | 0 |
| 65 | Targeting CD146 with a ⁶⁴ Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6525-34. | 7.1 | 54 |
| 66 | Separation of cyclotron-produced ⁴⁴ Sc from a natural calcium target using a dipentyl pentylphosphonate functionalized extraction resin. Applied Radiation and Isotopes, 2015, 95, 23-29. | 1.5 | 66 |
| 67 | Generation and Screening of Monoclonal Antibodies for ImmunoPET Imaging of IGF1R in Prostate Cancer. Molecular Pharmaceutics, 2014, 11, 3624-3630. | 4.6 | 7 |